Current Clinical Trials

  • All Open Trials

    TitleTrial ID#Disease IndicationCell-Biologic ProductPrincipal Investigator
    Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 Attached to TCRz and 4-1BB Signaling Domains in Patients with Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated with Cell Therapy (NCT02374333)13BT022Pediatric Leukemia/LymphomaHumanized CD19 redirected autologous T cells (huCART19)Shannon Maude, MD, PhD
    Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells Engineered to Contain Anti-CD19 Linked to TCRζ and 4-1BB Signaling Domains in Patients with Refractory or Relapsed Hodgkin Lymphoma (NCT02624258)14BT055Pediatric Hodgkin LymphomaCART-19 RNASusan Rheingold, MD
    Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Pediatric Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia (NCT02650414)15CT055Pediatric ALLCART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRζ:41BBStephan Grupp, MD, PhD
    A two cohort pilot study of the tocilizumab optimization timing for CART19 (CTL019) associated cytokine release syndrome (CRS) management in pediatric patients with CD19 expressing relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) (NCT02906371)16CT022Pediatric ALLmCART19 (early Toci)Stephan Grupp, MD PhD
    A Pilot Study to Evaluate the Safety and Tolerability of Escalating Doses of Autologous CD4 T-Cells Modified With Lentiviral Vector Expressing an HR2, C34-peptide Conjugated to the CXCR4 N-terminus in HIV-infected Subjects (NCT03020524)C34-CXCR4 (826035)HIVAutologous CD4 T-CellsPablo Tebas, MD
    Phase 1 Study of Human Chimeric Antigen Receptor Modified T Cells in Patients with Mesothelin Expressing Cancers (NCT03054298)UPCC02916Mesothelioma, Lung cancer, Pancreatic cancerhuCART-MESOJanos Tanyi, MD, PhD
    Phase I Clinical Trial of Autologous cMet Redirected Cells Administered Intravenously in Patients with Melanoma & Breast Carcinoma (NCT03060356)UPCC11916Melanoma and Breast CancerRNA CART-cMetTara C. Gangadhar, MD
    Phase 1 Study of Human Chimeric Antigen Receptor Modified T Cells in Patients with Pancreatic Cancer (NCT03323944)UPCC14217Pancreatic CancerhuCART-meso cellsMark O'Hara, MD
    Mature Dendritic Cell Vaccination Against Mutated Antigens in Patients With Advanced Melanoma (NCT03092453)UPCC17616MelanomaPulsed Dendritic CellsGerald Linette, MD
    Phase 1 Trial of autologous T cells engineered to express NY-ESO-1 and gene edited to eliminate endogenous TCR and PD-1 (NCT03399448)UPCC25416Sarcoma, Melanoma, MyelomaNY-ESO TCR/CRISPREdward Stadtmauer, MD
    Phase 1 study of PSMA-TGFBRDN CAR modified T cells in patients with advanced castrate resistant prostate cancer (NCT03089203)UPCC32816Prostate CancerPSMA-dnTGFbR CARNaomi Haas, MD
    Phase 2 Study of CD19-directed Chimeric Antigen Receptor-modified T cells (CART19) for Adult Patients with Minimal Residual Disease During Upfront Treatment for Acute Lymphoblastic Leukemia (NCT02935543)UPCC39416Acute Lymphoblastic Leukemia mCART19 (for ALL MRD+)Noelle Frey, MD
    Up-front CART-BCMA With or Without huCART19 as Consolidation of Standard First or Second-Line Therapy for High-Risk Multiple MyelomaUPCC46417Multiple MyelomaCART-BCMA + CTL119 comboAlfred L. Garfall, MD
  • Open Cancer Trials

    TitleTrial ID#Disease IndicationCell-Biologic ProductPrincipal Investigator
    Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 Attached to TCRz and 4-1BB Signaling Domains in Patients with Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated with Cell Therapy (NCT02374333)13BT022Pediatric Leukemia/LymphomaHumanized CD19 redirected autologous T cells (huCART19)Shannon Maude, MD, PhD
    Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells Engineered to Contain Anti-CD19 Linked to TCRζ and 4-1BB Signaling Domains in Patients with Refractory or Relapsed Hodgkin Lymphoma (NCT02624258)14BT055Pediatric Hodgkin LymphomaCART-19 RNASusan Rheingold, MD
    Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Pediatric Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia (NCT02650414)15CT055Pediatric ALLAutologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB)Stephan Grupp, MD, PhD
    A two cohort pilot study of the tocilizumab optimization timing for CART19 (CTL019) associated cytokine release syndrome (CRS) management in pediatric patients with CD19 expressing relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) (NCT02906371)16CT022Pediatric ALLmCART19 (early Toci)Stephan Grupp, MD PhD
    Phase 1 Study of Human Chimeric Antigen Receptor Modified T Cells in Patients with Mesothelin Expressing Cancers (NCT03054298)UPCC02916Mesothelin expressing cancershuCART-MESOJanos Tanyi, MD, PhD
    Phase I Clinical Trial of Autologous cMet Redirected Cells Administered Intravenously in Patients with Melanoma & Breast Carcinoma (NCT03060356)UPCC11916Melanoma and Breast CancerRNA CART-cMetTara C. Gangadhar, MD
    Phase 1 Study of Human Chimeric Antigen Receptor Modified T Cells in Patients with Pancreatic CancerUPCC14217Pancreatic CancerhuCART-meso cellsMark O'Hara, MD
    Mature Dendritic Cell Vaccination Against Mutated Antigens in Patients With Advanced Melanoma (NCT03092453)UPCC17616MelanomaPulsed Dendritic CellsGerald Linette, MD
    Phase 1 Trial of autologous T cells engineered to express NY-ESO-1 and gene edited to eliminate endogenous TCR and PD-1 (NCT03399448)UPCC25416Sarcoma, Melanoma, MyelomaNY-ESO TCR/CRISPREdward Stadtmauer, MD
    Phase 1 study of PSMA-TGFBRDN CAR modified T cells in patients with advanced castrate resistant prostate cancer (NCT03089203)UPCC32816Prostate CancerPSMA-dnTGFbR CARNaomi Haas, MD
    Phase 2 Study of CD19-directed Chimeric Antigen Receptor-modified T cells (CART19) for Adult Patients with Minimal Residual Disease During Upfront Treatment for Acute Lymphoblastic Leukemia (NCT02935543)UPCC39416Acute Lymphoblastic LeukemiamCART19 (for ALL MRD+)Noelle Frey, MD
    Up-front CART-BCMA With or Without huCART19 as Consolidation of Standard First or Second-Line Therapy for High-Risk Multiple MyelomaUPCC46417Multiple MyelomaCART-BCMA + CTL119 comboAlfred L. Garfall, MD
  • Open HIV Trials

    TitleTrial ID#Disease IndicationCell-Biologic ProductPrincipal Investigator
    A Pilot Study to Evaluate the Safety and Tolerability of Escalating Doses of Autologous CD4 T-Cells Modified With Lentiviral Vector Expressing an HR2, C34-peptide Conjugated to the CXCR4 N-terminus in HIV-infected Subjects (NCT03020524)C34-CXCR4 (826035)HIVAutologous CD4 T-CellsPablo Tebas, MD